DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid peptide studied in sleep architecture research. Patients can request a telehealth evaluation through the TelosRX Telehealth Portal to discuss compounded access.
What Is DSIP?
DSIP is a small neuropeptide first identified in research on delta-wave sleep. It is studied in preclinical research for sleep and stress pathways.
DSIP is not an FDA-approved drug. It is available through compounding pharmacies under valid prescription.
Common Discussion Points
Patients often raise DSIP during evaluations for:
- Sleep architecture research interest
- Stress response discussions
- Recovery research applications
- Circadian biology exploration
A licensed provider determines clinical appropriateness individually.
Pre-PCAC July 2026 Regulatory Context
DSIP is under PCAC review ahead of the July 2026 meeting. Patients interested in compounded access should consult a licensed provider while it remains available.
How TelosRX Handles DSIP
TelosRX is an online-first telehealth service. Patient evaluation is asynchronous, and compounded medications are prepared through our licensed pharmacy partner.
- Step 1: Complete an asynchronous telehealth intake at TelosRX.
- Step 2: Licensed provider review.
- Step 3: Prescription issued if clinically appropriate.
- Step 4: Compounded DSIP ships discreetly to your door.
Important Compliance Information
DSIP is not FDA-approved. Compounded preparations are prepared under federal compounding regulations.
Prescriptions require evaluation by a licensed healthcare provider. Approval is not guaranteed. Individual results vary.
TelosRX operates under LegitScript-certified telehealth standards.
Start your private evaluation at TelosRX.